<b>Conclusion:</b> The combination therapy of dabrafenib and trametinib has been proven to be an effective method as a later-line therapy for metastatic melanoma patients with class II BRAF in-frame deletion mutations. The gene discussed is BRAF; the disease is metastatic melanoma.